Market revenue in 2021 | USD 64.7 million |
Market revenue in 2030 | USD 199.3 million |
Growth rate | 13.3% (CAGR from 2021 to 2030) |
Largest segment | Anthrax |
Fastest growing segment | Radiation/nuclear |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anthrax, Small Pox, Botulism, Radiation/nuclear |
Key market players worldwide | Altimmune Inc, Emergent BioSolutions Inc, Dynavax Technologies, SIGA Technologies Inc, Elusys Therapeutics, Ichor Medical Systems, Cleveland-Cliffs Inc, Bavarian Nordic A/S, Ology Bioservices, Alnylam Pharmaceuticals Inc, XOMA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biodefense market will help companies and investors design strategic landscapes.
Anthrax was the largest segment with a revenue share of 29.21% in 2021. Horizon Databook has segmented the India biodefense market based on anthrax, small pox, botulism, radiation/nuclear covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the India biodefense market , including forecasts for subscribers. This country databook contains high-level insights into India biodefense market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account